| Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach LR Tefas, B Sylvester, I Tomuta, A Sesarman, E Licarete, M Banciu, ... Drug design, development and therapy, 1605-1621, 2017 | 160 | 2017 |
| The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases A Sesarman, G Vidarsson, C Sitaru Cellular and molecular life sciences 67 (15), 2533-2550, 2010 | 102 | 2010 |
| Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells A Sesarman, L Tefas, B Sylvester, E Licarete, V Rauca, L Luput, L Patras, ... Pharmacological reports 70 (2), 331-339, 2018 | 98 | 2018 |
| Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment A Sesarman, L Tefas, B Sylvester, E Licarete, V Rauca, L Luput, L Patras, ... Drug delivery and translational research 9 (1), 260-272, 2019 | 84 | 2019 |
| Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita A Sesarman, AG Sitaru, F Olaru, D Zillikens, C Sitaru Journal of molecular medicine 86 (8), 951-959, 2008 | 76 | 2008 |
| Blocking Fcα receptor I on granulocytes prevents tissue damage induced by IgA autoantibodies LP van der Steen, JE Bakema, A Sesarman, F Florea, CW Tuk, G Kirtschig, ... The Journal of Immunology 189 (4), 1594-1601, 2012 | 74 | 2012 |
| T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita AG Sitaru, A Sesarman, S Mihai, MT Chiriac, D Zillikens, P Hultman, ... The journal of immunology 184 (3), 1596-1603, 2010 | 73 | 2010 |
| Optimization of prednisolone-loaded long-circulating liposomes via application of Quality by Design (QbD) approach B Sylvester, A Porfire, DM Muntean, L Vlase, L Lupuţ, E Licarete, ... Journal of liposome research 28 (1), 49-61, 2018 | 62 | 2018 |
| Binding of avian IgY to type VII collagen does not activate complement and leucocytes and fails to induce subepidermal blistering in mice A Sesarman, S Mihai, MT Chiriac, F Olaru, AG Sitaru, JM Thurman, ... British journal of dermatology 158 (3), 463-471, 2008 | 60 | 2008 |
| Trojan horse treatment based on PEG-coated extracellular vesicles to deliver doxorubicin to melanoma in vitro and in vivo L Patras, AE Ionescu, C Munteanu, R Hajdu, A Kosa, A Porfire, E Licarete, ... Cancer biology & therapy 23 (1), 1-16, 2022 | 54 | 2022 |
| Tumor-associated macrophages favor C26 murine colon carcinoma cell proliferation in an oxidative stress-dependent manner L Luput, E Licarete, A Sesarman, L Patras, MC Alupei, M Banciu Oncology reports 37 (4), 2472-2480, 2017 | 49 | 2017 |
| Efficiency of photodynamic therapy on WM35 melanoma with synthetic porphyrins: Role of chemical structure, intracellular targeting and antioxidant defense I Baldea, DE Olteanu, P Bolfa, RM Ion, N Decea, M Cenariu, M Banciu, ... Journal of Photochemistry and Photobiology B: Biology 151, 142-152, 2015 | 47 | 2015 |
| Overcoming intrinsic doxorubicin resistance in melanoma by anti-angiogenic and anti-metastatic effects of liposomal prednisolone phosphate on tumor microenvironment E Licarete, VF Rauca, L Luput, D Drotar, I Stejerean, L Patras, B Dume, ... International journal of molecular sciences 21 (8), 2968, 2020 | 37 | 2020 |
| The flavonoid luteolin inhibits Fcγ-dependent respiratory burst in granulocytes, but not skin blistering in a new model of pemphigoid in adult mice E Oswald, A Sesarman, CW Franzke, U Wölfle, L Bruckner-Tuderman, ... PLoS One 7 (2), e31066, 2012 | 34 | 2012 |
| Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin A Sesarman, D Muntean, B Abrudan, L Tefas, B Sylvester, E Licarete, ... Journal of Liposome Research 31 (1), 1-10, 2021 | 33 | 2021 |
| In vivo double targeting of C26 colon carcinoma cells and microenvironmental protumor processes using liposomal simvastatin L Luput, E Licarete, DM Drotar, AL Nagy, A Sesarman, L Patras, ... Journal of Cancer 9 (2), 440, 2018 | 31 | 2018 |
| A screening study for the development of simvastatin-doxorubicin liposomes, a co-formulation with future perspectives in colon cancer therapy CI Barbălată, AS Porfire, A Sesarman, VF Rauca, M Banciu, D Muntean, ... Pharmaceutics 13 (10), 1526, 2021 | 30 | 2021 |
| Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5‐fluorouracil in vivo L Luput, A Sesarman, A Porfire, M Achim, D Muntean, T Casian, L Patras, ... Cancer science 111 (4), 1344-1356, 2020 | 27 | 2020 |
| Biologically Active Ajuga Species Extracts Modulate Supportive Processes for Cancer Cell Development VF Rauca, L Vlase, T Casian, A Sesarman, AM Gheldiu, A Mocan, ... Frontiers in Pharmacology 10, 334, 2019 | 27 | 2019 |
| Active tumor-targeting nano-formulations containing simvastatin and doxorubicin inhibit melanoma growth and angiogenesis G Negrea, VF Rauca, MS Meszaros, L Patras, L Luput, E Licarete, ... Frontiers in pharmacology 13, 870347, 2022 | 26 | 2022 |
